The Asia Pacific Parenteral Nutrition Market is expected to witness market growth of 9.3% CAGR during the forecast period (2021-2027).
The consumption of parenteral and amino acid-rich products is driven by the growing cases of hepatic insufficiency, protein-energy malnutrition, and renal insufficiency. Moreover, the substantial enhancements in parenteral nutrition like usage of indirect calorimetry and lipid emulsions optimizations are expected to boost the growth of the parenteral nutrition market in the next few years. Furthermore, some of the factors such as huge spending on the overall growth of the healthcare industry by the government bodies and private enterprises of various nations and increase in the adoption rate of parenteral nutrition products by the healthcare industry are responsible for the growth of the parenteral nutrition market.
Malnutrition is one the most common cause of inflammatory bowel disease (IBD) among a large population in both under-developed and developing countries of this region. As many of the countries of the region were hit hard by the outbreak of the COVID-19 pandemic, parenteral nutrition played a pivotal role in the treatment of the COVID-19 infection-associated malnutrition in patients across the world.
Moreover, the increase in the occurrence of chronic disorders like cancer, Crohn’s disease, HIV, and others are expected to fuel the growth of the regional parenteral nutrition market during the forecasting period. Furthermore, numerous premature babies get nutrition via parenteral nutrition. Intravenous solutions have been a crucial component of the healthcare system of many countries, allowing doctors & nurses to provide hydration to their patients, substitute loss of blood volume, and administer drugs. Therefore, these factors are set to boost the demand for parenteral nutrition in the regional market.
The China market dominated the Asia Pacific Parenteral Lipid Emulsion Market by Country in 2020, thereby, achieving a market value of $205.1 million by 2027. The Japan market is exhibiting a CAGR of 9.5% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 9.5% during (2021 - 2027).
Based on Nutrient Type, the market is segmented into Single Dose Amino Acid Solution, Parenteral Lipid Emulsion, Carbohydrates, Trace Elements, and Vitamins & Minerals. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Vifor Pharma Management Ltd., Baxter International, Inc., Allergan PLC (AbbVie), B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Grifols S.A., Pfizer, Inc., ICU Medical, Inc., Anhui Medipharm Co., Ltd. and Aculife Healthcare Private Limited.
Scope of the Study
Market Segments Covered in the Report:
By Nutrient Type
- Single Dose Amino Acid Solution
- Parenteral Lipid Emulsion
- Carbohydrates
- Trace Elements,
- Vitamins & Minerals
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Vifor Pharma Management Ltd.
- Baxter International, Inc.
- Allergan PLC (AbbVie)
- B.Braun Melsungen AG
- Fresenius SE & Co. KGaA
- Grifols S.A.
- Pfizer, Inc.
- ICU Medical, Inc.
- Anhui Medipharm Co., Ltd.
- Aculife Healthcare Private Limited
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Companies Mentioned
- Vifor Pharma Management Ltd.
- Baxter International, Inc.
- Allergan PLC (AbbVie)
- B. Braun Melsungen AG
- Fresenius SE & Co. KGaA
- Grifols S.A.
- Pfizer, Inc.
- ICU Medical, Inc.
- Anhui Medipharm Co., Ltd.
- Aculife Healthcare Private Limited
Methodology
LOADING...
